Jan K. Öhrström, M.D., joined the Avigen board in 2007. He is the Chief Clinical Officer and Executive Vice President of MediQuest Therapeutics, Inc., a specialty pharmaceutical company in Bothell, Washington. From 2000 to July 2007, Dr. Öhrström held various positions at ZymoGenetics, Inc., a biotech company, including Senior Vice President, Business Development from 2006 to 2007 and prior to that, Senior Vice President of Development and Chief Medical Officer. From 1990 to 1999, Dr. Öhrström held various positions at Novo Nordisk A/S, based in Denmark, including Director, Worldwide Development Portfolio. Prior to that, Dr. Öhrström was head of Strategic Marketing at Novo Nordisk, where he led the early launches of Gabitril and NovoSeven. He also served as Medical Director for Novo Nordisk Pharmaceuticals, Inc., located in Princeton, New Jersey. Dr. Öhrström earned his M.D. from the University of Copenhagen in 1984 and did six years of clinical practice in Neurology/Neurosurgery in Sweden and Denmark. During his clinical experience, he served as Clinical Investigator and Assistant Professor.